Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
This study is for the treatment of non-small cell lung cancer.
Primary disease category: Cancer
Secondary disease categories: Cancer, Lung Cancer
Sponsor: Southwest Oncology Group
Protocol number: EA5142
Projected enrollment dates: September 2016 to May 2018
Official study title: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
ClinicalTrials.gov page:
http://www.clinicaltrials.gov/show/NCT02595944